Last updated on 2022-07-04

Journal of Clinical Oncology
Research Hotspot & Journal Scope - pts

Homepage · Submit Manuscript · Wikipedia

Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.3501

Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).

Timothy Iveson · Alberto Sobrero · Takayuki Yoshino · Ioannis Sougklakos · Fang-Shu Ou · Jeffery P. Meyers · Qian Shi · Mark P Saunders · Roberto Labianca · Takeharu Yamanaka · Ioannis Boukovinas · Niels Henrik Hollander · Valter Torri · Kentaro Yamazaki · Vassilis Georgoulias · Sara Lonardi · Andrea Harkin · Gerardo Rosati · James Paul ·

Medicine
PDF

Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.9526

Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up.

Alexander Guminski · Annette M. Lim · Nikhil I. Khushalani · Chrysalyne D. Schmults · Leonel F. Hernandez-Aya · Badri Modi · Lara Dunn · Brett G. M. Hughes · Anne Lynn S. Chang · Axel Hauschild · Michael R. Migden · Ralf Gutzmer · Murad Alam · Vladimir Jankovic · Elizabeth Stankevich · Jocelyn Booth · S Li · Israel Lowy · Matthew G. Fury · Danny Rischin ·

Medicine
PDF

Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.8516

Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.

Jyoti Malhotra · Petros Nikolinakos · Ticiana Leal · Jonathan M. Lehman · Daniel Morgensztern · Jyoti D. Patel · John Wrangle · Giuseppe Curigliano · Eric Dansin · Laurent Greillier · Melissa L. Johnson · Neal Ready · Gilles Robinet · Satwant Lally · Shekman Wong · Emin Avsar · Ricardo Valenzuela · Charity D. Scripture · Giovanni Selvaggi · Benjamin Besse ·

Medicine
PDF

Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.4_SUPPL.191

Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: Results from the Know Your Tumor (KYT) program.

Michael J. Pishvaian · Edik M. Blais · Jonathan R. Brody · Davendra Sohal · Andrew Eugene Hendifar · Vincent Chung · Sameh Mikhail · Lola Rahib · Emily E. Lyons · Lisa Tibbetts · Subha Madhavan · Lynn M. Matrisian · Emanuel F. Petricoin ·

Medicine
PDF

Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.7_SUPPL.600

Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): Phase I results.

Molika Emmeline Keeler · Elizabeth R. Kessler · Brandon Bernard · Sarah Weisdack · Kathryn Breaker · Mali Wold · Donna Ertz · David Weitzenkamp · Thomas W. Flaig · Elaine Tat Lam ·

Medicine
PDF

BackgroundPathophysiological concepts in delirium are not sufficient to define objective biomarkers suited to improve clinical approaches.

7, 86% female) who were interviewed using the Clinician-Administered PTSD Scale-5 and completed self-reported measures of ER and rumination.

This study demonstrates the possibility of generating alternative actuation system concepts optimized for multifunctional requirements, not limited to small local improvements of existing architectures.

Effects were partially retained even controlling for co-occurring PTSD symptoms.

Moreover, whereas SUD patients without PTSD evidenced stability in IGT performance across scripts, those with PTSD exhibited significantly lower risk-taking on the IGT following the trauma (vs.

Explore More Sentence Examples

Highly Related Keywords from pts